APO Research
Talk to an analyst

APO RESEARCH · REPORT

Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Outlook and Growth Opportunities 2026

27 December 2025197 pages

Choose your research edition.

Industry ResearchParoxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market include Chugai Pharmaceutical, Regeneron Pharmaceuticals, Novartis, Roche, Amgen, Omeros Corporation, NovelMed, AstraZeneca and Apellis Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Company

Chugai Pharmaceutical

Regeneron Pharmaceuticals

Novartis

Roche

Amgen

Omeros Corporation

NovelMed

AstraZeneca

Apellis Pharmaceuticals

Alexion

Akari Therapeutics

Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Type

Oral Drugs

Injectable Drugs

Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Application

Pharmaceutical and Biotechnology Companies

Clinical

Others

Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs industry.

Chapter 3: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Trends Table 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Drivers Table 3. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Opportunities and Challenges Table 4. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Restraints Table 5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Share by Company (2021-2026) Table 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Company (Units) & (2021-2026) Table 8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company, Product Type & Application Table 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Drugs Table 18. Significant Companies of Injectable Drugs Table 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Type (2021-2026) & (Units) Table 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Type (2027-2032) & (Units) Table 22. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type (2021-2026) Table 28. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Pharmaceutical and Biotechnology Companies Table 30. Significant Companies of Clinical Table 31. Significant Companies of Others Table 32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 33. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Application (2021-2026) & (Units) Table 34. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Application (2027-2032) & (Units) Table 35. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application (2021-2026) Table 41. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application (2027-2032) Table 42. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 43. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2021-2026) & (Units) Table 44. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region (2021-2026) Table 45. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2027-2032) & (Units) Table 46. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region (2027-2032) Table 47. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Region (2021-2026) Table 50. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Region (2027-2032) Table 52. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 55. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026) & (Units) Table 57. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2021-2026) Table 58. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2027-2032) & (Units) Table 59. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2027-2032) Table 60. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Market Share by Country (2027-2032) Table 64. Chugai Pharmaceutical Company Information Table 65. Chugai Pharmaceutical Business Overview Table 66. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 68. Chugai Pharmaceutical Recent Development Table 69. Regeneron Pharmaceuticals Company Information Table 70. Regeneron Pharmaceuticals Business Overview Table 71. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 73. Regeneron Pharmaceuticals Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 78. Novartis Recent Development Table 79. Roche Company Information Table 80. Roche Business Overview Table 81. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 83. Roche Recent Development Table 84. Amgen Company Information Table 85. Amgen Business Overview Table 86. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 88. Amgen Recent Development Table 89. Omeros Corporation Company Information Table 90. Omeros Corporation Business Overview Table 91. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 93. Omeros Corporation Recent Development Table 94. NovelMed Company Information Table 95. NovelMed Business Overview Table 96. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 98. NovelMed Recent Development Table 99. AstraZeneca Company Information Table 100. AstraZeneca Business Overview Table 101. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 103. AstraZeneca Recent Development Table 104. Apellis Pharmaceuticals Company Information Table 105. Apellis Pharmaceuticals Business Overview Table 106. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 108. Apellis Pharmaceuticals Recent Development Table 109. Alexion Company Information Table 110. Alexion Business Overview Table 111. Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 113. Alexion Recent Development Table 114. Akari Therapeutics Company Information Table 115. Akari Therapeutics Business Overview Table 116. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio Table 118. Akari Therapeutics Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Distributors List Table 122. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Image Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (2021-2032) & (Units) Figure 5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Drugs Image Figure 10. Injectable Drugs Image Figure 11. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type (2021-2032) Figure 17. Pharmaceutical and Biotechnology Companies Image Figure 18. Clinical Image Figure 19. Others Image Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injectable Drugs
Applications
  • Pharmaceutical and Biotechnology Companies
  • Clinical
  • Others
Companies covered
  • Chugai Pharmaceutical
  • Regeneron Pharmaceuticals
  • Novartis
  • Roche
  • Amgen
  • Omeros Corporation
  • NovelMed
  • AstraZeneca
  • Apellis Pharmaceuticals
  • Alexion
  • Akari Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Dynamics
  1. 2.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Trends
  2. 2.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Drivers
  3. 2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Opportunities and Challenges
  4. 2.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Restraints
3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market by Company
  1. 3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Ranking (2024-2026)
  6. 3.6 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Product Type and Application
  8. 3.8 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market by Type
  1. 4.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Type Introduction
  2. 4.1.1 Oral Drugs
  3. 4.1.2 Injectable Drugs
  4. 4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Type
  5. 4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Type
  9. 4.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type (2021-2032)
5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market by Application
  1. 5.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Application Introduction
  2. 5.1.1 Pharmaceutical and Biotechnology Companies
  3. 5.1.2 Clinical
  4. 5.1.3 Others
  5. 5.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Application
  6. 5.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Application
  10. 5.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application (2021-2032)
6 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Regional Sales and Value Analysis
  1. 6.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2027-2032)
  5. 6.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Country, 2025 VS 2032
7 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2027-2032)
  6. 7.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chugai Pharmaceutical
  2. 8.1.1 Chugai Pharmaceutical Company Information
  3. 8.1.2 Chugai Pharmaceutical Business Overview
  4. 8.1.3 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  6. 8.1.5 Chugai Pharmaceutical Recent Developments
  7. 8.2 Regeneron Pharmaceuticals
  8. 8.2.1 Regeneron Pharmaceuticals Company Information
  9. 8.2.2 Regeneron Pharmaceuticals Business Overview
  10. 8.2.3 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  12. 8.2.5 Regeneron Pharmaceuticals Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Omeros Corporation
  32. 8.6.1 Omeros Corporation Company Information
  33. 8.6.2 Omeros Corporation Business Overview
  34. 8.6.3 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  36. 8.6.5 Omeros Corporation Recent Developments
  37. 8.7 NovelMed
  38. 8.7.1 NovelMed Company Information
  39. 8.7.2 NovelMed Business Overview
  40. 8.7.3 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  42. 8.7.5 NovelMed Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Apellis Pharmaceuticals
  50. 8.9.1 Apellis Pharmaceuticals Company Information
  51. 8.9.2 Apellis Pharmaceuticals Business Overview
  52. 8.9.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  54. 8.9.5 Apellis Pharmaceuticals Recent Developments
  55. 8.10 Alexion
  56. 8.10.1 Alexion Company Information
  57. 8.10.2 Alexion Business Overview
  58. 8.10.3 Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  60. 8.10.5 Alexion Recent Developments
  61. 8.11 Akari Therapeutics
  62. 8.11.1 Akari Therapeutics Company Information
  63. 8.11.2 Akari Therapeutics Business Overview
  64. 8.11.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
  66. 8.11.5 Akari Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Value Chain Analysis
  2. 9.1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Mode & Process
  6. 9.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Distributors
  9. 9.2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst